Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAB BioAtla	$0.35 -5.0%	$0.41	$0.24 ▼ $2.53	$21.65M	0.91	906,919 shs	1.38 million shs
CYTK Cytokinetics	$37.23 -4.3%	$33.08	$29.31 ▼ $61.38	$4.64B	0.59	1.53 million shs	1.37 million shs
MLAB Mesa Laboratories	$70.05 -6.8%	$100.50	$68.65 ▼ $155.12	$413.32M	0.86	59,609 shs	175,333 shs
ZEAL Zealand Pharma A/S	$17.59	$17.67	$9.93 ▼ $32.94	$818.60M	1.45	4,965 shs	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAB BioAtla	-3.74%	-4.14%	-4.95%	+14.45%	-79.52%
CYTK Cytokinetics	+0.54%	+6.29%	+19.51%	-1.49%	-31.52%
MLAB Mesa Laboratories	-4.93%	-16.81%	-18.98%	-32.93%	-33.05%
ZEAL Zealand Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAB BioAtla	2.237 of 5 stars	3.3	1.0	0.0	0.0	2.7	2.5	0.6
CYTK Cytokinetics	4.0425 of 5 stars	4.5	1.0	0.0	4.6	2.1	0.8	0.0
MLAB Mesa Laboratories	3.2361 of 5 stars	3.0	3.0	0.8	0.0	2.9	2.5	1.3
ZEAL Zealand Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAB BioAtla	2.50	Moderate Buy	$5.00	1,320.45% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	90.50% Upside
MLAB Mesa Laboratories	2.00	Hold	$130.00	85.58% Upside
ZEAL Zealand Pharma A/S	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCAB, MLAB, ZEAL, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
5/30/2025	MLAB Mesa Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$120.00 ➝ $100.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/14/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
5/13/2025	CYTK Cytokinetics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $53.00
5/7/2025	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$82.00 ➝ $80.00
5/7/2025	CYTK Cytokinetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$86.00 ➝ $80.00
5/2/2025	CYTK Cytokinetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$47.00 ➝ $41.00
5/2/2025	CYTK Cytokinetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $72.00
4/24/2025	CYTK Cytokinetics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$55.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAB BioAtla	$11M	1.87	N/A	N/A	$0.25 per share	1.41
CYTK Cytokinetics	$18.47M	240.74	N/A	N/A	($1.15) per share	-32.37
MLAB Mesa Laboratories	$240.98M	1.60	$11.43 per share	6.13	$29.42 per share	2.38
ZEAL Zealand Pharma A/S	$46.54M	17.59	N/A	N/A	$3.38 per share	5.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAB BioAtla	-$69.78M	-$1.22	0.00	N/A	N/A	N/A	-373.47%	-116.55%	8/6/2025 (Estimated)
CYTK Cytokinetics	-$589.53M	-$5.29	0.00	N/A	N/A	-3,201.47%	N/A	-43.75%	8/6/2025 (Estimated)
MLAB Mesa Laboratories	-$1.97M	-$0.37	9.61	8.03	N/A	-0.82%	27.51%	9.78%	8/5/2025 (Estimated)
ZEAL Zealand Pharma A/S	-$161.99M	-$4.09	N/A	N/A	N/A	-565.44%	-111.04%	-56.54%	N/A

Latest BCAB, MLAB, ZEAL, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BCAB BioAtla	-$0.29	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CYTK Cytokinetics	-$1.32	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q1 2026	MLAB Mesa Laboratories	$2.46	N/A	N/A	N/A	$60.45 million	N/A
5/6/2025	Q1 2025	BCAB BioAtla	-$0.28	-$0.29	-$0.01	-$0.26	N/A	N/A
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
MLAB Mesa Laboratories	$0.64	0.91%	N/A	N/A	N/A
ZEAL Zealand Pharma A/S	N/A	N/A	N/A	N/A	N/A

Latest BCAB, MLAB, ZEAL, and CYTK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/7/2025	MLAB Mesa Laboratories	quarterly	$0.16	0.7%	8/29/2025	8/29/2025	9/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAB BioAtla	N/A	2.35	2.35
CYTK Cytokinetics	N/A	5.99	5.99
MLAB Mesa Laboratories	0.48	0.63	0.47
ZEAL Zealand Pharma A/S	0.93	4.79	4.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAB BioAtla	77.23%
CYTK Cytokinetics	N/A
MLAB Mesa Laboratories	90.60%
ZEAL Zealand Pharma A/S	1.73%

Insider Ownership

Company	Insider Ownership
BCAB BioAtla	11.50%
CYTK Cytokinetics	2.70%
MLAB Mesa Laboratories	4.40%
ZEAL Zealand Pharma A/S	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAB BioAtla	60	58.42 million	51.70 million	Optionable
CYTK Cytokinetics	250	119.43 million	116.20 million	Optionable
MLAB Mesa Laboratories	680	5.50 million	5.26 million	Not Optionable
ZEAL Zealand Pharma A/S	355	46.54 million	45.51 million	Not Optionable

BCAB, MLAB, ZEAL, and CYTK Headlines

Recent News About These Companies

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

July 18 at 1:20 PM | markets.businessinsider.com

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

July 18 at 12:30 PM | globenewswire.com

Zealand Pharma A/S. (ZLDPF) Institutional Holdings | Nasdaq

July 11, 2025 | nasdaq.com

Zealand Pharma A/S. (ZLDPF) Analyst Research | Nasdaq

July 11, 2025 | nasdaq.com

Stock Movers: Sainsbury's, Zealand Pharma, Taylor Wimpey

July 1, 2025 | bloomberg.com

Zealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for More

June 20, 2025 | biospace.comB

Positive results for Zealand’s GLP-1/GLP-2 receptor dual agonist dapiglutide

June 20, 2025 | thepharmaletter.comT

Prothena to lay off majority of staff; Zealand shares obesity drug data

June 20, 2025 | biopharmadive.comB

Zealand Pharma’s 46% Stock Slump Makes New Obesity Drug Critical

June 20, 2025 | bloomberg.com

Zealand Pharma announces positive topline results from phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

June 20, 2025 | pharmabiz.comP

Zealand’s GLP-2 candidate shows early weight loss results

June 18, 2025 | statnews.comS

Zealand Pharma’s GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks

June 18, 2025 | fiercebiotech.comF

Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

June 18, 2025 | globenewswire.com

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

June 6, 2025 | globenewswire.com

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

June 2, 2025 | globenewswire.com

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

May 27, 2025 | globenewswire.com

European stocks close higher after Trump delays 50% tariffs on EU; Zealand Pharma pops 10%

May 26, 2025 | msn.com

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

May 22, 2025 | finance.yahoo.com

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

May 22, 2025 | finance.yahoo.com

Zealand Pharma Appoints Chief Development Officer

May 20, 2025 | contractpharma.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB, MLAB, ZEAL, and CYTK Company Descriptions

BioAtla NASDAQ:BCAB

$0.35 -0.02 (-5.02%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 +0.01 (+2.27%)

As of 07:49 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Cytokinetics NASDAQ:CYTK

$37.23 -1.66 (-4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$37.21 -0.02 (-0.06%)

As of 07:59 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Mesa Laboratories NASDAQ:MLAB

$70.05 -5.08 (-6.76%)

Closing price 04:00 PM Eastern

Extended Trading

$70.00 -0.05 (-0.07%)

As of 04:10 PM Eastern

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Zealand Pharma A/S NASDAQ:ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time